To the Editor: The impressive effects of the tyrosine kinaseinhibitor STI571 (imatinib mesylate) in chronic myeloid leukemiawere confirmed in the large trial by Kantarjian et al. (Feb.28 issue).1 We would like to report a new side effect of thedrug.
Between December 1999 and June 2001, we treated 133 patientswith chronic myeloid leukemia with imatinib mesylate accordingto Novartis Pharma protocols.1,2 Among these 133 patients, 5men and 4 women (median age, 63.4 years; range, 53 to 75) withgray hair before treatment had progressive repigmentation ofthe hair (on the head in 8 patients and . . . [Full Text of this Article]
This article has been cited by other articles:
Hofer, A. C., Tran, R. T., Aziz, O. Z., Wright, W., Novelli, G., Shay, J., Lewis, M.
(2005). Shared Phenotypes Among Segmental Progeroid Syndromes Suggest Underlying Pathways of Aging. Journals of Gerontology Series A: Biological Sciences and Medical Sciences
60: 10-20
[Abstract][Full Text]
Guilhot, F.
(2004). Indications for Imatinib Mesylate Therapy and Clinical Management. The Oncologist
9: 271-281
[Abstract][Full Text]
Smith, K. J., Jacobson, E., Hamza, S., Skelton, H.
(2004). Unexplained Hypereosinophilia and the Need for Cytogenetic and Molecular Genetic Analyses. Arch Dermatol
140: 584-588
[Abstract][Full Text]
Moss, K. G., Toner, G. C., Cherrington, J. M., Mendel, D. B., Laird, A. D.
(2003). Hair Depigmentation Is a Biological Readout for Pharmacological Inhibition of KIT in Mice and Humans. J. Pharmacol. Exp. Ther.
307: 476-480
[Abstract][Full Text]